Erratum: Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial (The Lancet (2016) 388(10059) (2479–2491)(S0140673616320505)(10.1016/S0140-6736(16)32050-5));Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

The Lancet

Volumn 388, Issue 10059, 2016, Pages 2479-2491

  Serruys, Patrick W ^a   Chevalier, Bernard ^b   Sotomi, Yohei ^c   Cequier, Angel ^d   Carrié, Didier ^e   Piek, Jan J ^c   Van Boven, Ad J ^f   Dominici, Marcello ^g   Dudek, Dariusz ^h   McClean, Dougal ⁱ   Helqvist, Steffen ^j   Haude, Michael ^k   Reith, Sebastian ^l   de Sousa Almeida, Manuel ^m   Campo, Gianluca ⁿ   Iñiguez, Andrés ^o   Sabaté, Manel ^p   Windecker, Stephan ^q   Onuma, Yoshinobu ^r,s  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Institut Jacques Cartier   (France)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e CHU RANGUEIL   (France)

^f MEDICAL CENTER LEEUWARDEN   (Netherlands)

^g Department of Medical Oncology   (Italy)

^h JAGIELLONIAN UNIVERSITY   (Poland)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k Lukaskrankenhaus GmbH   (Germany)

^l UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^m HOSPITAL DE SANTA CRUZ   (Portugal)

ⁿ Cardiovascular Institute   (Italy)

^o University Hospital of Vigo   (Spain)

^p HOSPITAL CLÍNIC   (Spain)

^q UNIVERSITY OF BERN   (Switzerland)

^r ERASMUS MEDICAL CENTER   (Netherlands)

^s CARDIALYSIS   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRATE; BIOMATERIAL; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BIORESORBABLE SCAFFOLD; CONTROLLED STUDY; DUAL ANTIPLATELET THERAPY; EVEROLIMUS ELUTING CORONARY STENT; EXERCISE TEST; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; METAL STENT; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEATTLE ANGINA QUESTIONNAIRE SCORE; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CORONARY STENOSIS; DRUG ELUTING STENT; INTERVENTIONAL ULTRASONOGRAPHY; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; SELF EXPANDABLE METALLIC STENT; TREATMENT OUTCOME; UTILIZATION;

ABSORBABLE IMPLANTS; BIOCOMPATIBLE MATERIALS; CORONARY STENOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL ISCHEMIA; SELF EXPANDABLE METALLIC STENTS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84996503761     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30515-9     Document Type: Erratum

References (27)

1. 1 Waksman, R, Biodegradable stents: they do their job and disappear. J Invasive Cardiol 18 (2006), 70–74.
2. 2 Diletti, R, Serruys, PW, Farooq, V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164 (2012), 654–663.
3. 3 Serruys, PW, Chevalier, B, Dudek, D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385 (2015), 43–54.
4. 4 Suryapranata, H, Maas, A, MacLeod, DC, de Feyter, PJ, Verdouw, PD, Serruys, PW, Coronary vasodilatory action of elgodipine in coronary artery disease. Am J Cardiol 69 (1992), 1171–1177.
5. 5 Suryapranata, H, Serruys, PW, De Feyter, PJ, Verdouw, PD, Hugenholtz, PG, Coronary vasodilatory action after a single dose of nicorandil. Am J Cardiol 61 (1988), 292–297.
6. 6 Spertus, JA, Winder, JA, Dewhurst, TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 25 (1995), 333–341.
7. 7 Camm, AJ, Lüscher, TF, Serruys, PW, The ESC textbook of cardiovascular medicine, 2009, Oxford University Press, Oxford.
8. 8 Cutlip, DE, Windecker, S, Mehran, R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
9. 9 Gomez-Lara, J, Brugaletta, S, Diletti, R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 32 (2011), 294–304.
10. 10 Hamilos, MI, Ostojic, M, Beleslin, B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 51 (2008), 2123–2129.
11. 11 Maier, W, Windecker, S, Kung, A, et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 105 (2002), 2373–2377.
12. 12 Serruys, PW, Onuma, Y, Garcia-Garcia, HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9 (2014), 1271–1284.
13. 13 Shin, DI, Kim, PJ, Seung, KB, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 48 (2007), 553–567.
14. 14 Togni, M, Windecker, S, Wenaweser, P, et al. Deleterious effect of coronary brachytherapy on vasomotor response to exercise. Circulation 110 (2004), 135–140.
15. 15 Onuma, Y, Sotomi, Y, Shiomi, H, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention 12 (2016), 1090–1101.
16. 16 Sotomi, Y, Onuma, Y, Suwannasom, P, et al. Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?. EuroIntervention 12 (2016), e998–1008.
17. 17 Sotomi, Y, Ishibashi, Y, Suwannasom, P, et al. Acute gain in minimal lumen area following implantation of everolimus-eluting ABSORB biodegradable vascular scaffolds or Xience metallic stents: intravascular ultrasound assessment from the ABSORB II trial. JACC Cardiovasc Interv 9 (2016), 1216–1227.
18. 18 Serruys, PW, Ormiston, J, van Geuns, RJ, et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J Am Coll Cardiol 67 (2016), 766–776.
19. 19 Ishibashi, Y, Muramatsu, T, Nakatani, S, et al. Incidence and potential mechanism(s) of post-procedural rise of cardiac biomarker in patients with coronary artery narrowing after implantation of an everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent. JACC Cardiovasc Interv 8 (2015), 1053–1063.
20. 20 Collet, C, Asano, T, Sotomi, Y, et al. Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studies. Minerva Cardioangiol, 2016 published online Sept 14.
21. 21 Raber, L, Magro, M, Stefanini, GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125 (2012), 1110–1121.
22. 22 Karanasos, A, Van Mieghem, N, van Ditzhuijzen, N, et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv, 8, 2015, 10.1161/CIRCINTERVENTIONS.114.002369.
23. 23 Raber, L, Brugaletta, S, Yamaji, K, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol 66 (2015), 1901–1914.
24. 24 Sotomi, Y, Suwannasom, P, Serruys, PW, Onuma, Y, Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention, 2016, 10.4244/EIJ-D-16-00471 published online Oct 25.
25. 25 Ishibashi, Y, Nakatani, S, Sotomi, Y, et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv 8 (2015), 1715–1726.
26. 26 Suwannasom, P, Sotomi, Y, Ishibashi, Y, et al. The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the ABSORB II trial. JACC Cardiovasc Interv 9 (2016), 1231–1242.
27. 27 Puricel, S, Cuculi, F, Weissner, M, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol 67 (2016), 921–931.